Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients.

Gutierrez-Bautista, Juan FranciscoRodriguez-Nicolas, AntonioRosales-Castillo, AntonioLopez-Ruz, Miguel AngelMartin-Casares, Antonia MaríaFernandez-Rubiales, AlonsoAnderson, PerGarrido, FedericoRuiz-Cabello, FranciscoLopez-Nevot, Miguel Angel2023-05-032023-05-032021-08-05Gutiérrez-Bautista JF, Rodriguez-Nicolas A, Rosales-Castillo A, López-Ruz MÁ, Martín-Casares AM, Fernández-Rubiales A, et al. Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients. J Microbiol Immunol Infect. 2022 Jun;55(3):421-427.http://hdl.handle.net/10668/22323Human leukocyte antigen (HLA) plays an important role in immune responses to infections, especially in the development of acquired immunity. Given the high degree of polymorphisms that HLA molecules present, some will be more or less effective in controlling SARS-CoV-2 infection. We wanted to analyze whether certain polymorphisms may be involved in the protection or susceptibility to COVID-19. We studied the polymorphisms in HLA class I (HLA-A, -B and -C) and II (HLA-DRB1 and HLA-DQB1) molecules in 450 patients who required hospitalization for COVID-19, creating one of the largest HLA-typed patient cohort to date. Our results show that there is no relationship between HLA polymorphisms or haplotypes and susceptibility or protection to COVID-19. Our results may contribute to resolve the contradictory data on the role of HLA polymorphisms in COVID-19 infection.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/COVID-19HLA polymorphismsSARS-CoV-2AllelesCOVID-19Gene FrequencyGenetic Predisposition to DiseaseHLA-A AntigensHLA-DRB1 ChainsHaplotypesHistocompatibility Antigens Class IHumansSARS-CoV-2Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients.research article34475005open accessAlelosAntígenos HLA-AAntígenos de histocompatibilidad clase ICadenas HLA-DRB1Frecuencia de los genesHaplotiposHumanosPredisposición genética a la enfermedadSARS-CoV-210.1016/j.jmii.2021.08.0091995-9133PMC8384756https://doi.org/10.1016/j.jmii.2021.08.009https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384756/pdf